2016-08-18
Ark Biosciences Initiates VICTOR Study
Ark Biosciences Inc. announced today that dosing with AK0529, its leading antiviral drug against respiratory syncytial virus (RSV), has commenced in infants hospitalized with RSV infection in the VICTOR (Viral Inhibition in Children...
know more >